JP2013538788A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013538788A5 JP2013538788A5 JP2013516846A JP2013516846A JP2013538788A5 JP 2013538788 A5 JP2013538788 A5 JP 2013538788A5 JP 2013516846 A JP2013516846 A JP 2013516846A JP 2013516846 A JP2013516846 A JP 2013516846A JP 2013538788 A5 JP2013538788 A5 JP 2013538788A5
- Authority
- JP
- Japan
- Prior art keywords
- nmol
- hour
- formulation
- stable formulation
- stable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009472 formulation Methods 0.000 claims description 93
- 239000000203 mixture Substances 0.000 claims description 93
- 102100022146 Arylsulfatase A Human genes 0.000 claims description 42
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 claims description 42
- 238000007913 intrathecal administration Methods 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 31
- 210000001519 tissue Anatomy 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 229920000136 polysorbate Polymers 0.000 claims description 12
- 229950008882 polysorbate Drugs 0.000 claims description 12
- 239000004094 surface-active agent Substances 0.000 claims description 12
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims description 11
- 229910019142 PO4 Inorganic materials 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 11
- 210000003169 central nervous system Anatomy 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 239000010452 phosphate Substances 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 230000002093 peripheral effect Effects 0.000 claims description 10
- 210000004556 brain Anatomy 0.000 claims description 9
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 7
- 229940068977 polysorbate 20 Drugs 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 238000009825 accumulation Methods 0.000 claims description 6
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 6
- 229920001296 polysiloxane Polymers 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 5
- 210000002569 neuron Anatomy 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 210000005250 spinal neuron Anatomy 0.000 claims description 5
- 230000003376 axonal effect Effects 0.000 claims description 4
- 239000005388 borosilicate glass Substances 0.000 claims description 4
- 210000004705 lumbosacral region Anatomy 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- 208000016192 Demyelinating disease Diseases 0.000 claims description 3
- 206010012305 Demyelination Diseases 0.000 claims description 3
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 3
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 3
- 229940101027 polysorbate 40 Drugs 0.000 claims description 3
- 229940113124 polysorbate 60 Drugs 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 229940071643 prefilled syringe Drugs 0.000 claims description 3
- 210000000278 spinal cord Anatomy 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical class O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 206010022773 Intracranial pressure increased Diseases 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 230000033289 adaptive immune response Effects 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 208000003906 hydrocephalus Diseases 0.000 claims description 2
- 238000002650 immunosuppressive therapy Methods 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 230000004807 localization Effects 0.000 claims description 2
- 239000008176 lyophilized powder Substances 0.000 claims description 2
- 230000002132 lysosomal effect Effects 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 210000003007 myelin sheath Anatomy 0.000 claims description 2
- 210000004498 neuroglial cell Anatomy 0.000 claims description 2
- 210000004248 oligodendroglia Anatomy 0.000 claims description 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 2
- 210000004786 perivascular cell Anatomy 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 239000000088 plastic resin Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 125000000185 sucrose group Chemical group 0.000 claims description 2
- 210000001835 viscera Anatomy 0.000 claims description 2
- 210000004885 white matter Anatomy 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims 2
- 208000012287 Prolapse Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 3
- 208000015439 Lysosomal storage disease Diseases 0.000 description 2
- 230000001934 delay Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002641 enzyme replacement therapy Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35885710P | 2010-06-25 | 2010-06-25 | |
| US61/358,857 | 2010-06-25 | ||
| US36078610P | 2010-07-01 | 2010-07-01 | |
| US61/360,786 | 2010-07-01 | ||
| US38786210P | 2010-09-29 | 2010-09-29 | |
| US61/387,862 | 2010-09-29 | ||
| US201161435710P | 2011-01-24 | 2011-01-24 | |
| US61/435,710 | 2011-01-24 | ||
| US201161442115P | 2011-02-11 | 2011-02-11 | |
| US61/442,115 | 2011-02-11 | ||
| US201161476210P | 2011-04-15 | 2011-04-15 | |
| US61/476,210 | 2011-04-15 | ||
| US201161495268P | 2011-06-09 | 2011-06-09 | |
| US61/495,268 | 2011-06-09 | ||
| PCT/US2011/041926 WO2011163650A2 (en) | 2010-06-25 | 2011-06-25 | Methods and compositions for cns delivery of arylsulfatase a |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015246952A Division JP6346162B2 (ja) | 2010-06-25 | 2015-12-18 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013538788A JP2013538788A (ja) | 2013-10-17 |
| JP2013538788A5 true JP2013538788A5 (enExample) | 2014-08-14 |
| JP6045493B2 JP6045493B2 (ja) | 2016-12-14 |
Family
ID=46888844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516846A Active JP6045493B2 (ja) | 2010-06-25 | 2011-06-25 | アリールスルファターゼａのｃｎｓ送達の方法および組成物 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9770410B2 (enExample) |
| EP (3) | EP3626257B1 (enExample) |
| JP (1) | JP6045493B2 (enExample) |
| KR (5) | KR102094094B1 (enExample) |
| CN (1) | CN103282046B (enExample) |
| AU (5) | AU2011270670B2 (enExample) |
| BR (1) | BR112012033216B1 (enExample) |
| CA (1) | CA2803003C (enExample) |
| CY (2) | CY1122282T1 (enExample) |
| DK (1) | DK2585104T3 (enExample) |
| ES (1) | ES2754776T3 (enExample) |
| HR (1) | HRP20191923T1 (enExample) |
| IL (3) | IL291556B2 (enExample) |
| LT (1) | LT2585104T (enExample) |
| ME (1) | ME03647B (enExample) |
| MX (2) | MX382443B (enExample) |
| NZ (2) | NZ605873A (enExample) |
| PL (2) | PL2585104T3 (enExample) |
| RS (1) | RS59468B1 (enExample) |
| RU (1) | RU2671503C2 (enExample) |
| SI (1) | SI2585104T1 (enExample) |
| SM (1) | SMT201900589T1 (enExample) |
| TW (1) | TWI667037B (enExample) |
| UA (1) | UA115650C2 (enExample) |
| WO (1) | WO2011163650A2 (enExample) |
| ZA (1) | ZA201300675B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3626258T (pt) | 2010-06-25 | 2021-10-19 | Shire Human Genetic Therapies | Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase |
| HRP20191924T1 (hr) | 2010-06-25 | 2020-01-10 | Shire Human Genetic Therapies, Inc. | Postupci i sastavi za isporuku iduronat-2-sulfataze u cns |
| DK2588130T3 (en) | 2010-06-25 | 2016-10-24 | Shire Human Genetic Therapies | Cns delivery of therapeutic agents |
| NZ605873A (en) | 2010-06-25 | 2015-02-27 | Shire Human Genetic Therapies | Methods and compositions for cns delivery of arylsulfatase a |
| MX2013000320A (es) | 2010-06-25 | 2013-06-05 | Shire Human Genetic Therapies | Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa. |
| WO2013096899A2 (en) | 2011-12-23 | 2013-06-27 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
| CN119979504A (zh) | 2013-01-09 | 2025-05-13 | 武田药品工业株式会社 | 含用于纯化芳基硫酸酯酶a的方法 |
| RU2692251C2 (ru) * | 2013-05-15 | 2019-06-24 | Риджентс Оф Зэ Юниверсити Оф Миннесота | Опосредованный аденоассоциированным вирусом перенос генов в центральную нервную систему |
| US10208734B2 (en) * | 2015-04-23 | 2019-02-19 | Continuum Dynamics, Inc. | Lift-driven wind turbine with force canceling blade configuration |
| WO2017009255A1 (en) * | 2015-07-10 | 2017-01-19 | Synthon Biopharmaceuticals B.V. | Compositions comprising antibody-duocarmycin drug conjugates |
| CN108883162A (zh) * | 2016-02-17 | 2018-11-23 | 夏尔人类遗传性治疗公司 | 用于芳基硫酸酯酶a的cns递送的方法和组合物 |
| NZ788906A (en) * | 2016-06-01 | 2025-07-25 | Servier Ip Uk Ltd | Formulations of polyalkylene oxide-asparaginase and methods of making and using the same |
| KR102471458B1 (ko) | 2016-12-28 | 2022-11-25 | 제이씨알 파마 가부시키가이샤 | 동결건조 제제 |
| TWI835747B (zh) | 2017-09-22 | 2024-03-21 | 賓州大學委員會 | 用於治療黏多醣病 ii 型之基因治療 |
| KR20200107984A (ko) | 2017-12-19 | 2020-09-16 | 샤이어 휴먼 지네틱 테라피즈 인크. | 정제된 아릴설파타아제 a 및 이의 조성물 |
| WO2020004368A1 (ja) * | 2018-06-25 | 2020-01-02 | Ｊｃｒファーマ株式会社 | 蛋白質含有水性液剤 |
| WO2020227166A1 (en) * | 2019-05-03 | 2020-11-12 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of metachromatic leukodystrophy |
| WO2021061517A1 (en) * | 2019-09-23 | 2021-04-01 | University Of Washington | Assay of arylsulfatase a enzymatic activity in dried blood spots by mass spectrometry and fluorometry |
| WO2024176112A1 (en) | 2023-02-21 | 2024-08-29 | Takeda Pharmaceutical Company Limited | Large scale production of recombinant arylsulfatase a and compositions thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4743265A (en) | 1986-04-23 | 1988-05-10 | Dij Catheter Corp | Articulated catheter placement device |
| US5863782A (en) | 1995-04-19 | 1999-01-26 | Women's And Children's Hospital | Synthetic mammalian sulphamidase and genetic sequences encoding same |
| US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| ATE225184T1 (de) * | 1997-08-22 | 2002-10-15 | Seikagaku Kogyo Co Ltd | Arzneimittel zur behandlung von durch hernie gestörter intervertebraler bandscheibe |
| WO2000034451A1 (en) | 1998-12-07 | 2000-06-15 | Pharming Intellectual Property B.V. | Treatment of pompe's disease |
| US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
| US20020052311A1 (en) | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| US20020099025A1 (en) | 1999-12-30 | 2002-07-25 | Heywood James A. | Treatment of neurological disorders |
| US6866844B2 (en) | 2002-11-07 | 2005-03-15 | Biomarin Pharmaceutical Inc. | Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US7629309B2 (en) | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| US20040005309A1 (en) | 2002-05-29 | 2004-01-08 | Symbiontics, Inc. | Targeted therapeutic proteins |
| ATE384736T1 (de) | 2001-04-30 | 2008-02-15 | Zystor Therapeutics Inc | Subzelluläres targeting von therapeutischen proteinen |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| WO2003032913A2 (en) | 2001-10-16 | 2003-04-24 | Symbiontics Inc. | Methods and compositions for targeting proteins across the blood brain barrier |
| JP5570677B2 (ja) | 2002-04-25 | 2014-08-13 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | α−ガラクトシダーゼＡ欠損症の治療 |
| EP1514106A4 (en) | 2002-05-29 | 2007-05-09 | Zystor Therapeutics Inc | TARGETED THERAPEUTIC PROTEINS |
| US20040248262A1 (en) | 2003-01-22 | 2004-12-09 | Koeberl Dwight D. | Constructs for expressing lysomal polypeptides |
| CA2525236C (en) | 2003-06-20 | 2015-03-24 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20050026823A1 (en) | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| NZ548871A (en) | 2004-01-30 | 2009-06-26 | Shire Pharmaceuticals Ireland | Use of arylsulfatase A for treating metachromatic leukodystrophy |
| WO2005074888A2 (en) | 2004-02-03 | 2005-08-18 | Biodelivery Sciences International, Inc. | Replacement enzyme cochleates |
| WO2005077093A2 (en) | 2004-02-06 | 2005-08-25 | Biomarin Pharmaceutical Inc. | Manufacture of highly phosphorylated lysosomal enzymes and uses thereof |
| ES2344302T3 (es) | 2004-02-10 | 2010-08-24 | Zystor Therapeutics , Inc. | Alfa glucosidasa acida y fragmentos de la misma. |
| US20050208090A1 (en) | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
| JPWO2006121199A1 (ja) | 2005-05-11 | 2008-12-18 | 日本ケミカルリサーチ株式会社 | 脂質小胞体組成物 |
| CN104771402A (zh) | 2005-06-08 | 2015-07-15 | 阿米库斯治疗学公司 | 溶酶体酶编码基因突变相关的cns紊乱的治疗 |
| AR059089A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
| CN101410408A (zh) * | 2006-04-04 | 2009-04-15 | 希尔制药爱尔兰有限责任公司 | 用于浓缩多肽的方法 |
| PL2631242T3 (pl) * | 2006-04-04 | 2023-03-20 | Takeda Pharmaceutical Company Limited | Sposób zatężania polipeptydu |
| GB0611463D0 (en) | 2006-06-09 | 2006-07-19 | Novartis Ag | Organic compounds |
| US20080140056A1 (en) | 2006-12-06 | 2008-06-12 | Medtronic, Inc. | Method for delivering large molecules to the brain |
| US20090041741A1 (en) | 2007-03-06 | 2009-02-12 | Saint Louis University | Modified enzyme and treatment method |
| BRPI0815416A2 (pt) * | 2007-08-15 | 2014-10-21 | Amunix Inc | Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos |
| TWI661833B (zh) | 2007-11-30 | 2019-06-11 | 百慕達商艾伯維生物技術有限責任公司 | 蛋白質調配物及製造其之方法 |
| US7722865B2 (en) * | 2008-01-18 | 2010-05-25 | Biomarin Pharmaceutical Inc. | Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof |
| US20110223147A1 (en) | 2008-05-07 | 2011-09-15 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| US8436489B2 (en) | 2009-06-29 | 2013-05-07 | Lightsail Energy, Inc. | Compressed air energy storage system utilizing two-phase flow to facilitate heat exchange |
| MX2013000320A (es) | 2010-06-25 | 2013-06-05 | Shire Human Genetic Therapies | Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa. |
| HRP20191924T1 (hr) | 2010-06-25 | 2020-01-10 | Shire Human Genetic Therapies, Inc. | Postupci i sastavi za isporuku iduronat-2-sulfataze u cns |
| DK2588130T3 (en) | 2010-06-25 | 2016-10-24 | Shire Human Genetic Therapies | Cns delivery of therapeutic agents |
| NZ605873A (en) | 2010-06-25 | 2015-02-27 | Shire Human Genetic Therapies | Methods and compositions for cns delivery of arylsulfatase a |
| PT3626258T (pt) | 2010-06-25 | 2021-10-19 | Shire Human Genetic Therapies | Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase |
| US20110318327A1 (en) | 2010-06-25 | 2011-12-29 | Shire Human Genetic Therapies, Inc. | Treatment of sanfilippo syndrome type b |
| EP2588132A4 (en) | 2010-06-25 | 2014-10-15 | Shire Human Genetic Therapies | METHOD AND COMPOSITIONS FOR DELIVERING BETA GALACTOCEREBROSIDASE INTO THE CNS |
| JP2012062312A (ja) | 2010-08-19 | 2012-03-29 | Yoshikatsu Eto | ハンター症候群の治療剤 |
-
2011
- 2011-06-25 NZ NZ605873A patent/NZ605873A/en unknown
- 2011-06-25 LT LT11799037T patent/LT2585104T/lt unknown
- 2011-06-25 SI SI201131776T patent/SI2585104T1/sl unknown
- 2011-06-25 US US13/168,963 patent/US9770410B2/en active Active
- 2011-06-25 UA UAA201214685A patent/UA115650C2/uk unknown
- 2011-06-25 AU AU2011270670A patent/AU2011270670B2/en active Active
- 2011-06-25 PL PL11799037T patent/PL2585104T3/pl unknown
- 2011-06-25 IL IL291556A patent/IL291556B2/en unknown
- 2011-06-25 ES ES11799037T patent/ES2754776T3/es active Active
- 2011-06-25 SM SM20190589T patent/SMT201900589T1/it unknown
- 2011-06-25 EP EP19192508.0A patent/EP3626257B1/en active Active
- 2011-06-25 KR KR1020187014958A patent/KR102094094B1/ko active Active
- 2011-06-25 ME MEP-2019-298A patent/ME03647B/me unknown
- 2011-06-25 CA CA2803003A patent/CA2803003C/en active Active
- 2011-06-25 RS RSP20191354 patent/RS59468B1/sr unknown
- 2011-06-25 PL PL19192508T patent/PL3626257T3/pl unknown
- 2011-06-25 MX MX2017000156A patent/MX382443B/es unknown
- 2011-06-25 EP EP11799037.4A patent/EP2585104B1/en active Active
- 2011-06-25 WO PCT/US2011/041926 patent/WO2011163650A2/en not_active Ceased
- 2011-06-25 HR HRP20191923TT patent/HRP20191923T1/hr unknown
- 2011-06-25 MX MX2013000323A patent/MX344795B/es active IP Right Grant
- 2011-06-25 KR KR1020217034302A patent/KR102537084B1/ko active Active
- 2011-06-25 EP EP21189310.2A patent/EP3964230A1/en active Pending
- 2011-06-25 KR KR1020137001752A patent/KR101997935B1/ko active Active
- 2011-06-25 KR KR1020207008105A patent/KR102318997B1/ko active Active
- 2011-06-25 BR BR112012033216-3A patent/BR112012033216B1/pt active IP Right Grant
- 2011-06-25 NZ NZ702799A patent/NZ702799A/en unknown
- 2011-06-25 RU RU2012154574A patent/RU2671503C2/ru active
- 2011-06-25 DK DK11799037.4T patent/DK2585104T3/da active
- 2011-06-25 JP JP2013516846A patent/JP6045493B2/ja active Active
- 2011-06-25 KR KR1020237017347A patent/KR102720061B1/ko active Active
- 2011-06-25 CN CN201180040802.XA patent/CN103282046B/zh active Active
- 2011-06-27 TW TW100122533A patent/TWI667037B/zh active
-
2012
- 2012-12-20 IL IL223758A patent/IL223758B/en active IP Right Grant
-
2013
- 2013-01-25 ZA ZA2013/00675A patent/ZA201300675B/en unknown
-
2017
- 2017-04-06 AU AU2017202289A patent/AU2017202289B2/en active Active
-
2019
- 2019-06-11 AU AU2019204051A patent/AU2019204051B2/en active Active
- 2019-11-13 CY CY20191101190T patent/CY1122282T1/el unknown
-
2020
- 2020-04-06 IL IL273854A patent/IL273854B/en unknown
-
2021
- 2021-09-24 AU AU2021236557A patent/AU2021236557B2/en active Active
- 2021-11-02 CY CY20211100942T patent/CY1124910T1/el unknown
-
2025
- 2025-04-03 AU AU2025202376A patent/AU2025202376A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013538788A5 (enExample) | ||
| JP2016040335A5 (enExample) | ||
| JP2013530988A5 (enExample) | ||
| JP2024097029A5 (enExample) | ||
| CN106139133B (zh) | 艾杜糖醛酸-2-硫酸酯酶的cns递送的方法和组合物 | |
| KR102603430B1 (ko) | 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들 | |
| RU2012154574A (ru) | Способы и композиции для доставки в цнс арилсульфатазы а | |
| US9579366B2 (en) | Recombinant human NaGlu protein and uses thereof | |
| RU2012154576A (ru) | Способы и композиции для доставки к цнс гепаран-n-сульфатазы | |
| JP5923177B2 (ja) | 新規な遺伝子伝達用組成物 | |
| US9603908B2 (en) | Subcutaneous administration of iduronate-2-sulfatase | |
| WO2012023623A2 (ja) | ハンター症候群の治療剤 | |
| JP2024102370A (ja) | アリールスルファターゼａのｃｎｓ送達のための方法および組成物 | |
| US20190083583A1 (en) | Enzyme replacement therapy in mucopolysaccharidosis iiib patients | |
| US20250288548A1 (en) | Intranasal baclofen | |
| CN101014359A (zh) | 通过将神经胶质细胞系来源的神经营养因子直接注入到未定带内治疗人帕金森病的方法 | |
| RU2022129038A (ru) | Способы и композиции для доставки в цнс арилсульфатазы а | |
| JP2025510150A (ja) | パーキンソン病の処置のための方法および組成物 | |
| WO2021065768A1 (ja) | 空間形成剤、皮下投与製剤および空間形成方法 | |
| CN119971017A (zh) | 一种hmpv疫苗组合物 | |
| GREGORIADIS | stability or increase the volume of aqueous spaces (3 | |
| EA043909B1 (ru) | Способы и композиции для доставки арилсульфатазы a в цнс |